In membranous glomerulonephritis, rituximab therapy is effective in two-thirds of patients and is presumed to act through a reduction in the levels of pathogenic anti -phospholipase A2 receptor or anti-thrombospondin type 1 domain-containing protein 7A antibodies23. The gene discussed is THSD1; the disease is membranous glomerulonephritis.